FBTA 05

Drug Profile

FBTA 05

Alternative Names: Bi20; FBTA05; Lymphomun

Latest Information Update: 27 Jan 2016

Price : $50

At a glance

  • Originator TRION Pharma
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors; CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued B cell lymphoma; Chronic lymphocytic leukaemia

Most Recent Events

  • 30 Sep 2015 No recent reports of development identified - Phase-I/II for Chronic lymphocytic leukaemia in Germany (IV)
  • 30 Sep 2015 No recent reports of development identified - Phase-I/II for B-cell lymphoma in Germany (IV)
  • 13 Jun 2010 Efficacy, adverse events and pharmacokinetics data from a compassionate use trial in Non-Hodgkin's lymphoma and Chronic lymphocytic leukaemia presented at the 15th Congress of the European Hematology Association (EHA-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top